1. Home
  2. OUST vs IMNM Comparison

OUST vs IMNM Comparison

Compare OUST & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ouster Inc.

OUST

Ouster Inc.

HOLD

Current Price

$34.32

Market Cap

2.9B

Sector

Technology

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$27.18

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OUST
IMNM
Founded
2015
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.5B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
OUST
IMNM
Price
$34.32
$27.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
10
Target Price
$39.25
$32.80
AVG Volume (30 Days)
2.6M
1.1M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
48.56
51.40
EPS
N/A
N/A
Revenue
$169,384,000.00
$6,941,000.00
Revenue This Year
$33.20
N/A
Revenue Next Year
$37.27
$1,127.34
P/E Ratio
N/A
N/A
Revenue Growth
52.46
N/A
52 Week Low
$16.40
$8.67
52 Week High
$63.79
$30.06

Technical Indicators

Market Signals
Indicator
OUST
IMNM
Relative Strength Index (RSI) 38.81 53.34
Support Level $31.95 $18.72
Resistance Level $50.62 $30.06
Average True Range (ATR) 2.91 1.45
MACD -0.98 -0.18
Stochastic Oscillator 2.70 39.49

Price Performance

Historical Comparison
OUST
IMNM

About OUST Ouster Inc.

Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and the Pacific, Europe, the Middle East, and Africa. It derives maximum revenue from the Americas. The Company operates as one reportable and operating segment, which relates to the sale and production of lidar sensor kits.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: